Enzo Biochem Down 1.19% To $1.25 After Earnings

Enzo Biochem Inc (ENZ) reported less than expected earnings this afternoon for Q2 2024.

Enzo Biochem reported EPS loss of $0.00 per share. Profits rose 0% year-over-year after reporting an EPS loss of $0.23 per share in its year-ago quarter. The positive growth rate signals that the Healthcare company .

Revenues were upbeat at $8.6 million. That revenue figure represents a 47.65% decrease from the year ago quarter.

The stock is down 1.19% to $1.25 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

Trading in the five days leading up to the report earned Enzo Biochem a Bearish Sentiment Rank from InvestorsObserver.

Enzo Biochem has performed a little below average during the past few months. Before the report, Enzo Biochem received a Long-Term Technical Rank by InvestorsObserver of 37, putting it in the bottom half of stocks. The firm set a 52-week high on May 11, 2023 at $2.74 and set a 52-week low on March 15, 2023 at $1.

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.